Cellares rebuffed Bristol Myers Squibb’s criticism of its cell therapy manufacturing technology after BMS terminated a contract, citing concerns about commercial manufacturing readiness. Cellares said the partnership’s termination followed BMS’s assessment that the Cell Shuttle system was not up to standard. The dispute adds to broader scrutiny around cell therapy manufacturing transfer, consistency, and scale-up—where technical performance must align with timelines for clinical and commercial production. For sponsors, these conflicts can delay supply readiness and complicate program planning. Cellares’ response emphasizes the manufacturing platform’s intended value proposition and frames the disagreement as a technology-readiness mismatch rather than an operational failure by either party.